



CLINICAL TRIALS OF TEXAS, INC.

Promoting Health Through Research

Curriculum Vitae

David Ryan Dooley, MD

7940 Floyd Curl Drive, Suite 700
San Antonio, Texas 78229

7940 Floyd Curl Drive, Suite 900
San Antonio, Texas 78229

EDUCATION

- 1983-1987 Internship/Residency in Obstetrics and Gynecology, John Peter Smith Hospital, Fort Worth, Texas
- 1983 Doctor of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1979 Bachelors of Science in Pharmacy (with Highest Honors), University of Texas at Austin, Austin, Texas

LICENSE

- 1983 Texas Medical Board, # G4995

CERTIFICATION(S)

- 1999 American Board of Medical Specialties Board Certified in Obstetrics & Gynecology

PROFESSIONAL EXPERIENCE

- 2006-Present Institute for Women's Health, San Antonio, Texas
- 1987-2005 Private Practice, San Antonio, Texas

PROFESSIONAL MEMBERSHIPS

Diplomat, American Board of Obstetrics and Gynecology
American College of Obstetrics and Gynecology
Texas Medical Association
American Fertility Society
Association of Gynecologic Laparoscopists
Texas Society of Obstetricians and Gynecologists
Southern Medical Association

HOSPITAL AFFILIATIONS

SW Texas Methodist, San Antonio, Texas
St. Luke's Baptist Hospital, San Antonio, Texas

RESEARCH AFFILIATIONS

- 2006-Present Investigator, Clinical Trials of Texas, Inc., San Antonio, Texas

RESEARCH EXPERIENCE

2009-Present: A Multi-Center, Randomized, Active Controlled Study To Investigate The Efficacy And Safety Of Intravenous "Study Drug" In Patients With Iron Deficiency Anemia (IDA)

2009-Present: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of "Study Drug" In Subjects With Endometriosis

2008-Present: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of A Single Dose Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia In Subjects Who Are Not Dialysis Dependent

2008-Present: A Multicenter, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia

2008-Present: A Multicenter, Randomized, Double-Blind, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Doses Of "Study Drug" Versus Placebo In Women With Overactive Bladder

2008-2009: A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Uterine Fibroids

2008-2009: Efficacy And Safety Of "Study Drug" In The Treatment Of Moderate To Severe Vaginal Dryness And Vaginal Pain Associated With Sexual Activity, Symptoms Of Vulvar And Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 60 Mg Daily Dose With Placebo In Postmenopausal Women

2008-2009: A Multi-Center, Placebo Controlled, Safety And Efficacy Study Of "Study Drug" In Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy

2008-2009: A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Endometriosis-Extension Study

2007-2009: A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Endometriosis

2007-2009: An Open Label Study Of The Contraceptive Efficacy Of An Extended Regimen Of "Study Drug" And "Study Drug"

2007-2009: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia In Heavy Uterine Bleeding And Postpartum Patients

2007-2008: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation Of The Use Of Topically Administered "Study Drug" Versus Placebo In Subjects With Pain Associated With Fibrocystic Breast Disease

2006-2008: Long-Term Safety Of "Study Drug" Oral Daily Dose For The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women Without A Uterus: A 52-Week Open-Label Follow-Up To "Protocol"

2006-2008: Long-Term Safety Of 30 Mg And 60 Mg Oral Daily Doses Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women With An Intact Uterus: A 40-Week Randomized, Double-Blind, Placebo-Controlled, Follow-Up To "Protocol"

2006-2008: A Randomized, Placebo-Controlled Phase II Study Of Multiple Dosing Regimens Of Intravaginally Administered "Study Drug" Gel For The Treatment Of Cervical High Risk HPV Infection

2006-2008: Efficacy And Safety Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 30 Mg And 60 Mg Daily Doses With Placebo

Signature and Date